What is Arcturus Therapeutics Holdings Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Arcturus Therapeutics Holdings's Probability of Financial Distress (%) is 0.04%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Arcturus Therapeutics Holdings's Probability of Financial Distress (%)
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Probability of Financial Distress (%) falls into.
Arcturus Therapeutics Holdings Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -7.76 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.04% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description
Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
| Pad Chivukula |
officer: Chief Scientific Officer & COO |
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| Keith C Kummerfeld |
officer: See Remarks |
10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
| Magda Marquet |
director |
ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121 |
| John Markels |
director |
C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804 |
| Joseph E Payne |
director, 10 percent owner, officer: President and CEO |
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| Jing L. Marantz |
director |
C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
| Ultragenyx Pharmaceutical Inc. |
director, 10 percent owner |
60 LEVERONI COURT, NOVATO CA 94949 |
| Lance Kurata |
officer: Chief Legal Officer |
10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
| Andy Sassine |
officer: Chief Financial Officer |
82 DEVONSHIRE STREET, BOSTON MA 02109 |
| Steven George Hughes |
officer: Chief Development Officer |
6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| James F Barlow |
director |
2525 DUPONT DR, IRVINE CA 92612 |
| Edward W Holmes |
director |
C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208 |
| Peter C Farrell |
director |
RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
| Karah Herdman Parschauer |
director |
60 LEVERONI COURT, NOVATO CA 94949 |
Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARCT has been successfully added to your